市场调查报告书
商品编码
1262694
肿瘤市场——按癌症诊断和治疗、按癌症类型、按最终用户和预测,2023-2032 年Oncology Market - By Cancer Diagnostics & Treatment, By Cancer Type, By End-use & Forecast, 2023 - 2032 |
在全球癌症发病率上升的背景下,肿瘤学市场预计将从 2023 年到 2032 年经历显着增长。
根据世界卫生组织的统计,癌症是全球主要死因之一,预计到 2020 年将有大约 1000 万人死亡。 出于这个原因,需要广泛的治疗选择来治疗这种疾病。 化疗、手术和放疗等各种治疗方法被用于癌症治疗,因为它们在癌症治疗中不仅具有治愈作用,而且具有姑息作用。
新兴经济体的研究人员、政府官员和市场参与者的技术创新将进一步影响到 2032 年的行业增长。 例如,英国政府技术转让署 (GOTT) 已资助国家物理实验室开发新的超声技术以增强乳腺癌诊断。
肿瘤学行业分为癌症诊断和治疗、癌症、最终用途和地理。
基于癌症诊断和治疗,癌症诊断领域有望随着时间的推移提供有益的回报。 推动这一领域增长的基本因素包括癌症发病率的增加和该领域的技术进步。 也有人说,仅靠体格检查和生物标誌物检测来检测癌症是一项繁琐的工作,而影像学检查对于确诊癌症是必不可少的。 这种趋势正在推动对高级诊断成像的需求并推动市场增长。
至于癌症,肥胖、荷尔蒙失调和与衰老相关的风险增加导致乳腺癌发病率迅速增加,预计未来十年乳腺癌细分市场份额将大幅增长。 Cancer.net 的统计数据预测,到 2023 年,美国将有超过 43,500 人死于乳腺癌。 此外,新西兰和其他地方的 BreastScreen Aotearoa 等各种政府举措将通过为女性提供免费检测来进一步扩大市场规模。
近年来,肿瘤治疗通常在专科诊所进行。 这些医疗保健设施充当某些类型癌症治疗的先进癌症治疗设施。 在这些医疗机构进行癌症检测和筛查的先进技术和专业肿瘤学家的可用性进一步推动了业务的增长。
此外,不用说,用于筛查和诊断的先进技术的可用性将为患者提供有吸引力的癌症治疗机会。
从地理上讲,亚太地区可能会成为肿瘤学行业的热点。 根据该报告,预计 2023 年至 2032 年亚太地区肿瘤市场的复合年增长率将超过 11.5%。 该地区的增长可能是由于印度、日本和中国等国家的癌症病例激增。 顺便说一下,癌症登记数据显示,印度每年大约有 80 万例新癌症病例。
此外,亚太地区主要製药公司新开发的抗癌药物在当地人群中的意识不断增强,预计也将推动未来几年的市场增长。
Oncology Market is expected to garner commendable gains over 2023 to 2032, fueled by the growing cancer prevalence worldwide. As per WHO statistics, cancer is one of the leading causes of fatalities worldwide, resulting in nearly 10 million deaths in 2020. This calls for broad treatment options to treat the disease. Various therapies such as chemotherapy, surgery, and radiation therapy are employed in cancer therapy subject to the pivotal benefits in terms of providing palliative as well as curative effect in cancer treatment.
Technological innovations by researchers, government officials, and market players in developed economies would further influence the industry growth through 2032. For instance, the Government Office for Technology Transfer (GOTT), UK, funded the National Physical Laboratory's novel development of ultrasound technology to enhance breast cancer diagnosis.
The oncology industry is segmented into cancer diagnostics and treatment, cancer, end-use, and region.
Based on cancer diagnostics and treatment, the cancer diagnostics segment is slated to churn profitable returns over the due course of time. Fundamental factors driving the segmental growth include growing incidences of cancer and technological advancements in the space. In addition, detecting cancer with only physical exams or biomarker tests is noted to be a monotonous task while imaging test is essential for conformation. These trends thus prompt the demand for advanced imaging modalities, stimulating the market growth.
Considering the cancer, oncology market share from breast cancer segment would accrue massive gains over the next ten years, owing to the alarming breast cancer incidences due to rising obesity, hormonal imbalance cases, and age-related risks. As per Cancer.net statistics, it has been projected that breast cancer could lead to more than 43,500 deaths in the United States in 2023. Besides, various government efforts such as BreastScreen Aotearoa in New Zealand and other countries, providing free tests to women would further boost the market size.
Oncology treatment is being largely accommodated in specialty clinics over the recent years. These healthcare settings stand as advanced cancer care establishments that cater to specific types of cancer treatments. Increased availability of advanced technology for detection and screening and specialist oncologists across these settings would further encourage the business growth.
Not to mention, growing availability of advanced technology for screening and diagnosis would offer attractive opportunities to patients for cancer treatment.
Regionally, Asia Pacific is likely to emerge as a regional hotspot for oncology industry. As per reports, the APAC oncology market is predicted to grow at more than 11.5% CAGR between 2023 to 2032. The regional growth can be credited to the burgeoning cases of cancer in countries such as India, Japan, and China. For the record, a cancer registry data reveals that there would be approximately 800,000 new cancer cases in India every year.
Furthermore, growing cognizance among the regional population about the newly developed cancer medications by key pharmaceutical companies in the Asia Pacific would foster the regional market growth in the years ahead.